We are analyzing https://link.springer.com/article/10.1007/s10875-004-6245-2.

Title:
A Peptide Based on the Complementarity Determining Region 1 of a Human Monoclonal Autoantibody Ameliorates Spontaneous and Induced Lupus Manifestations in Correlation with Cytokine Immunomodulation | Journal of Clinical Immunology
Description:
A peptide based on the sequence of the complementarity determining region (CDR) 1 of a human monoclonal anti-DNA autoantibody that bears the 16/6 idiotype (16/6Id) was synthesized as a potential candidate for the treatment of SLE patients. The peptide, designated hCDR1, did not induce experimental SLE upon active immunization of mice. The ability of the peptide to treat an already established lupus that was either induced in BALB/c mice or developed spontaneously in (NZB × NZW)F1 mice was tested. Ten weekly injections of hCDR1 (200, 50 μg/mouse) given subcutaneously mitigated disease manifestations (e.g., leukopenia, proteinuria and kidney damage) and resulted in a prominent reduction in the dsDNA specific antibody titers. Furthermore, treatment with hCDR1 resulted in reduced secretion and expression of the “pathogenic” cytokines [i.e., INFγ, IL-1β, TNFα (in the induced model) and IL-10], whereas the immunosuppressive cytokine TGFβ was up-regulated. Thus, the significant ameliorating effects of hCDR1 are manifested at least partially via the immunomodulation of the cytokine profile. These results suggest that hCDR1 is a potential candidate for a novel treatment of SLE patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,734,772 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

google, scholar, lupus, systemic, mozes, immunol, peptide, mice, erythematosus, article, antidna, based, cytokine, zinger, pathogenic, dayan, sle, murine, human, monoclonal, induced, manifestations, experimental, disease, access, privacy, cookies, content, journal, immunology, region, autoantibody, treatment, hcdr, antibody, cytokines, proc, natl, acad, sci, springer, peptides, usa, clin, publish, search, complementarity, determining, immunomodulation, patients,

Topics {✒️}

jian-ping liu & edna mozes igg anti-dna antibodies anti-dna antibody reverses tumour necrosis factor-alpha month download article/chapter antigen-specific therapy murine anti-dna autoantibodies hla-linked autoimmunity anti-dna antibody related subjects murine lupus nephritis systemic lupus erythematosus systemic lupus erythematosus bh dj wallace anti-dna induced systemic lupus erithematosus privacy choices/manage cookies human-human hybridomas systemic immunological effects full article pdf consensus peptide based dubois’ lupus erithematosus lupus nephritis modulate lupus development springer semin immunopathol16 cytokine immunomodulation published induce experimental sle induced lupus manifestations delays disease onset antigen-specific regulatory immunosuppressive cytokine tgfβ cytokine genes injected european economic area complementarity determining region ten weekly injections significant ameliorating effects curr opin immunol10 th1/th2 balance complementarity determining regions complementarity-determining region-1 complementarity-determining regions vh4 gene segment hsu-lin sc variable region sequences amino acid sequences interferon-gamma mrna pathogenic autoantibody lupus-prone mice conditions privacy policy sle cytokine puzzle

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A Peptide Based on the Complementarity Determining Region 1 of a Human Monoclonal Autoantibody Ameliorates Spontaneous and Induced Lupus Manifestations in Correlation with Cytokine Immunomodulation
         description:A peptide based on the sequence of the complementarity determining region (CDR) 1 of a human monoclonal anti-DNA autoantibody that bears the 16/6 idiotype (16/6Id) was synthesized as a potential candidate for the treatment of SLE patients. The peptide, designated hCDR1, did not induce experimental SLE upon active immunization of mice. The ability of the peptide to treat an already established lupus that was either induced in BALB/c mice or developed spontaneously in (NZB × NZW)F1 mice was tested. Ten weekly injections of hCDR1 (200, 50 μg/mouse) given subcutaneously mitigated disease manifestations (e.g., leukopenia, proteinuria and kidney damage) and resulted in a prominent reduction in the dsDNA specific antibody titers. Furthermore, treatment with hCDR1 resulted in reduced secretion and expression of the “pathogenic” cytokines [i.e., INFγ, IL-1β, TNFα (in the induced model) and IL-10], whereas the immunosuppressive cytokine TGFβ was up-regulated. Thus, the significant ameliorating effects of hCDR1 are manifested at least partially via the immunomodulation of the cytokine profile. These results suggest that hCDR1 is a potential candidate for a novel treatment of SLE patients.
         datePublished:
         dateModified:
         pageStart:579
         pageEnd:590
         sameAs:https://doi.org/10.1007/s10875-004-6245-2
         keywords:
            Models of lupus
            CDR-based peptide
            cytokine immunomodulation
            disease amelioration
            Immunology
            Infectious Diseases
            Internal Medicine
            Medical Microbiology
         image:
         isPartOf:
            name:Journal of Clinical Immunology
            issn:
               1573-2592
               0271-9142
            volumeNumber:24
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers-Plenum Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:DROR LUGER
               affiliation:
                     name:The Weizmann Institute of Science
                     address:
                        name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                        type:PostalAddress
                     type:Organization
               type:Person
               name:MOLLY DAYAN
               affiliation:
                     name:The Weizmann Institute of Science
                     address:
                        name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                        type:PostalAddress
                     type:Organization
               type:Person
               name:HEIDY ZINGER
               affiliation:
                     name:The Weizmann Institute of Science
                     address:
                        name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                        type:PostalAddress
                     type:Organization
               type:Person
               name:JIAN-PING LIU
               affiliation:
                     name:The Weizmann Institute of Science
                     address:
                        name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                        type:PostalAddress
                     type:Organization
               type:Person
               name:EDNA MOZES
               affiliation:
                     name:The Weizmann Institute of Science
                     address:
                        name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A Peptide Based on the Complementarity Determining Region 1 of a Human Monoclonal Autoantibody Ameliorates Spontaneous and Induced Lupus Manifestations in Correlation with Cytokine Immunomodulation
      description:A peptide based on the sequence of the complementarity determining region (CDR) 1 of a human monoclonal anti-DNA autoantibody that bears the 16/6 idiotype (16/6Id) was synthesized as a potential candidate for the treatment of SLE patients. The peptide, designated hCDR1, did not induce experimental SLE upon active immunization of mice. The ability of the peptide to treat an already established lupus that was either induced in BALB/c mice or developed spontaneously in (NZB × NZW)F1 mice was tested. Ten weekly injections of hCDR1 (200, 50 μg/mouse) given subcutaneously mitigated disease manifestations (e.g., leukopenia, proteinuria and kidney damage) and resulted in a prominent reduction in the dsDNA specific antibody titers. Furthermore, treatment with hCDR1 resulted in reduced secretion and expression of the “pathogenic” cytokines [i.e., INFγ, IL-1β, TNFα (in the induced model) and IL-10], whereas the immunosuppressive cytokine TGFβ was up-regulated. Thus, the significant ameliorating effects of hCDR1 are manifested at least partially via the immunomodulation of the cytokine profile. These results suggest that hCDR1 is a potential candidate for a novel treatment of SLE patients.
      datePublished:
      dateModified:
      pageStart:579
      pageEnd:590
      sameAs:https://doi.org/10.1007/s10875-004-6245-2
      keywords:
         Models of lupus
         CDR-based peptide
         cytokine immunomodulation
         disease amelioration
         Immunology
         Infectious Diseases
         Internal Medicine
         Medical Microbiology
      image:
      isPartOf:
         name:Journal of Clinical Immunology
         issn:
            1573-2592
            0271-9142
         volumeNumber:24
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers-Plenum Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:DROR LUGER
            affiliation:
                  name:The Weizmann Institute of Science
                  address:
                     name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                     type:PostalAddress
                  type:Organization
            type:Person
            name:MOLLY DAYAN
            affiliation:
                  name:The Weizmann Institute of Science
                  address:
                     name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                     type:PostalAddress
                  type:Organization
            type:Person
            name:HEIDY ZINGER
            affiliation:
                  name:The Weizmann Institute of Science
                  address:
                     name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                     type:PostalAddress
                  type:Organization
            type:Person
            name:JIAN-PING LIU
            affiliation:
                  name:The Weizmann Institute of Science
                  address:
                     name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                     type:PostalAddress
                  type:Organization
            type:Person
            name:EDNA MOZES
            affiliation:
                  name:The Weizmann Institute of Science
                  address:
                     name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Clinical Immunology
      issn:
         1573-2592
         0271-9142
      volumeNumber:24
Organization:
      name:Kluwer Academic Publishers-Plenum Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Weizmann Institute of Science
      address:
         name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
         type:PostalAddress
      name:The Weizmann Institute of Science
      address:
         name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
         type:PostalAddress
      name:The Weizmann Institute of Science
      address:
         name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
         type:PostalAddress
      name:The Weizmann Institute of Science
      address:
         name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
         type:PostalAddress
      name:The Weizmann Institute of Science
      address:
         name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:DROR LUGER
      affiliation:
            name:The Weizmann Institute of Science
            address:
               name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
               type:PostalAddress
            type:Organization
      name:MOLLY DAYAN
      affiliation:
            name:The Weizmann Institute of Science
            address:
               name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
               type:PostalAddress
            type:Organization
      name:HEIDY ZINGER
      affiliation:
            name:The Weizmann Institute of Science
            address:
               name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
               type:PostalAddress
            type:Organization
      name:JIAN-PING LIU
      affiliation:
            name:The Weizmann Institute of Science
            address:
               name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
               type:PostalAddress
            type:Organization
      name:EDNA MOZES
      affiliation:
            name:The Weizmann Institute of Science
            address:
               name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
      name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
      name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
      name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
      name:Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(66)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.75s.

LINK . SPRINGER . COM {}